Literature DB >> 23024278

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Anna Pasetto1, Lars Frelin, Soo Aleman, Fredrik Holmström, Anette Brass, Gustaf Ahlén, Erwin D Brenndörfer, Volker Lohmann, Ralf Bartenschlager, Matti Sällberg, Antonio Bertoletti, Margaret Chen.   

Abstract

Virus-specific CTL with high levels of functional avidity have been associated with viral clearance in hepatitis C virus (HCV) infection and with enhanced protective immunity. In chronic HCV infection, lack of antiviral CTL is frequently observed. In this study, we aim to investigate novel HCV TCRs that differ in Ag specificity. This involved isolating new HCV-specific murine TCRs that recognize a conserved HLA-A2-restricted CTL epitope within the nonstructural protein (NS) 5A viral protein and comparing them with TCRs recognizing another conserved CTL target in the NS3 viral protein. This was done by expressing the TCRs in human T cells and analyzing the function of the resulting TCR-transduced T cells. Our result indicates that these TCRs are efficiently assembled in transduced human T cells. They recognize peptide-loaded targets and demonstrate polyfunctional features such as IL-2, IFN-γ, and TNF-α secretion. However, in contrast to NS3-specific TCRs, the NS5A TCR-transduced T cells consist of a smaller proportion of polyfunctional T cells and require more peptide ligands to trigger the effector functions, including degranulation. Despite the differences, NS5A TCRs show effective inhibition of HCV replication in human hepatoma cells with persistent HCV RNA replication. Moreover, cellular injury demonstrated by aspartate aminotransferase release and cell death is less significant in the hepatoma cells following coincubation with NS5A TCR-transduced T cells, which is a property consistent with noncytotoxic antiviral CTLs. Our results suggest that HCV TCR-transduced T cells may be promising for the treatment of patients with chronic HCV infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024278     DOI: 10.4049/jimmunol.1201613

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Authors:  Keisuke Ojiro; Xiaowang Qu; Hyosun Cho; Jang-June Park; Annelise Vuidepot; Nikolai Lissin; Peter E Molloy; Alan Bennett; Bent K Jakobsen; David E Kaplan; James L Riley; Kyong-Mi Chang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

2.  Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.

Authors:  Daniela Nascimento Silva; Michael Chrobok; Giulia Rovesti; Katie Healy; Arnika Kathleen Wagner; Panagiota Maravelia; Francesca Gatto; Massimiliano Mazza; Lucia Mazzotti; Volker Lohmann; Margaret Sällberg Chen; Matti Sällberg; Marcus Buggert; Anna Pasetto
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 3.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

4.  Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Authors:  Drew C Deniger; Anna Pasetto; Eric Tran; Maria R Parkhurst; Cyrille J Cohen; Paul F Robbins; Laurence Jn Cooper; Steven A Rosenberg
Journal:  Mol Ther       Date:  2016-03-05       Impact factor: 11.454

Review 5.  Emerging concepts in immunity to hepatitis C virus infection.

Authors:  Hugo R Rosen
Journal:  J Clin Invest       Date:  2013-10-01       Impact factor: 14.808

6.  TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.

Authors:  Timothy T Spear; Glenda G Callender; Jeffrey J Roszkowski; Kelly M Moxley; Patricia E Simms; Kendra C Foley; David C Murray; Gina M Scurti; Mingli Li; Justin T Thomas; Alexander Langerman; Elizabeth Garrett-Mayer; Yi Zhang; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-02-03       Impact factor: 6.968

Review 7.  Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies.

Authors:  Katie Healy; Anna Pasetto; Michał J Sobkowiak; Chai Fen Soon; Markus Cornberg; Soo Aleman; Margaret Sällberg Chen
Journal:  Cells       Date:  2020-06-16       Impact factor: 6.600

8.  Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.

Authors:  Chai Fen Soon; Shihong Zhang; Pothakamuri Venkata Suneetha; Dinler Amaral Antunes; Michael Peter Manns; Solaiman Raha; Christian Schultze-Florey; Immo Prinz; Heiner Wedemeyer; Margaret Sällberg Chen; Markus Cornberg
Journal:  Front Immunol       Date:  2019-09-04       Impact factor: 7.561

9.  Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Authors:  Anangi Balasiddaiah; Haleh Davanian; Soo Aleman; Anna Pasetto; Lars Frelin; Matti Sällberg; Volker Lohmann; Sarene Koh; Antonio Bertoletti; Margaret Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

10.  Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Authors:  Fredrik Holmström; Margaret Chen; Anangi Balasiddaiah; Matti Sällberg; Gustaf Ahlén; Lars Frelin
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.